KYV-102 / Kyverna - LARVOL DELTA

Third Quarter 2025 Highlights and Recent Business Updates:…KYV-102 (GlobeNewswire) - "Kyverna remains on track to file an investigational new drug (IND) application for KYV-102 in the fourth quarter of 2025."

IND • Systemic Lupus Erythematosus

KYV-102 (GlobeNewswire) - "Kyverna expects to file an investigational new drug (IND) application for KYV-102 in the fourth quarter of 2025. KYV-102 is produced with the Company’s next-generation proprietary whole blood, rapid manufacturing process, incorporating the same construct as KYV-101. KYV-102 provides the opportunity to broaden access through the elimination of apheresis."

IND • Systemic Lupus Erythematosus

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PRNewswire) - "Kyverna is currently advancing two Phase 1/2 trials in LN, KYSA-1 and KYSA-3. Kyverna has completed the dose-escalation cohort of KYSA-1 and is now treating patients at the target dose and expects to report Phase 1 data from both of these trials in the second half of 2025....Kyverna expects to file an investigational new drug application for KYV-102 in the second half of 2025."

IND • P1 data • Trial status • Lupus Nephritis